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Considerations regarding point-of-
care testing
To the Editor: I read with interest the article by Abbai et al.[1] 
regarding the evaluation of a point-of-care (POC) HbA1c analyser, 
which appeared in a recent issue of SAMJ. In the context of the 
current medical landscape in southern Africa, there is clearly a place 
for POC devices, but there are certain important caveats to their 
use – in particular with HbA1c – that end-users should be aware 
of and that were not touched on in the article. Firstly, importance 
of sample type: the Afinion AS100 analyser (Alere, South Africa 
(SA)) and most other POC devices would utilise finger-prick patient 
samples (capillary blood) for analysis in most clinical contexts. In the 
abovementioned article, the authors have not evaluated the diagnostic 
accuracy of the use of finger-prick samples compared with formal 
blood collection. Some studies have reported significant differences 
in composition of capillary v. venous blood. With regard to HbA1c, 
Schalk et al.[2] found capillary values of Hb to be significantly 
higher than the corresponding venous values. Incorrect capillary 
blood sampling can cause significantly inaccurate results. Secondly, 
importance of location: most POC devices are placed in non-
laboratory environments that are not temperature controlled and that 
do not have sufficient access to refrigeration. Many of the currently 
available POC devices and reagents have been designed to operate 
in more temperate climates. Extremes of environment, particularly 
the high temperatures experienced in SA, may affect the functioning 
of devices and stability of reagents. In the artice by Gounden and 
George[3] that evaluated various POC devices in the SA context, a 
scoring system was developed to evaluate the devices in terms of 
features, such as ability to be used in extremes of temperature, as well 
as other important considerations, such as information technology 
connectivity (to enable transmission of results to electronic medical 
record/laboratory information systems), water requirements and 
costs. These need to be considered when choosing a POC device. 
Thirdly, importance of interferences: Afinion HbA1c results are 
reported to be affected by the presence of fetal Hb (HbF).[4] Elevated 
HbF levels may be found in neonates, hereditary persistence of 
HbF, thalassaemias and late pregnancy. Fourthly, precision studies: 
precision performance forms the cornerstone for the assessment 
of clinical utility of a test or an instrument. Abbai et al.[1] have not 
presented data with regard to imprecision performance of the POC 
analyser for the tests evaluated. Shephard et al.[5] have proposed desirable 
imprecision goals for POC devices for HbA1c (coefficient of variation 
3%) and lipid parameters. The American Diabetes Association also 
provide recommendations for HbA1c precision. Abbai et al.[1] only 
evaluated performance of Afinion HbA1c with regard to correct 
categorisation of patients at one medical decision point (HbA1c 6.5%). 
As one of the primary roles of POC testing (POCT) is the monitoring 
of diabetic patients receiving treatment in order to allow for a more 
prompt change in management, evaluation at other important medical 
decision limits, e.g. HbA1c 7%, would have been clinically relevant. 
It must be emphasised that POCT also requires implementation of a 
complete quality management system that includes analysis of internal 
and external quality assurance samples.
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